TrialThe Journal of clinical endocrinology and metabolism2009

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.

David A D'Alessio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.